AstraZeneca's Vaccine Candidate Produces Antibodies and T-Cell Protection for Up to One Year Medicine & Technology Oct 26, 2020 With AstraZeneca's vaccine trials resuming worldwide, results have shown good immune responses in young and older adults alike. However, trials are yet to resume in the United States as volunteers await their second dose.
TECH & INNOVATION OpenAI’s Whisper Faces Scrutiny Over Accuracy, Experts Find 'Hallucinated' Text in Transcripts